MorphoSys Enrolls First Patient In Phase 1b/2a Clinical Trial For MOR103 Program In Rheumatoid Arthritis

Links shared publicly online about this topic.

  • 1,445
    total visits

MorphoSys Enrolls First Patient In Phase 1b/2a Clinical Trial For MOR103 Program In Rheumatoid Arthritis

medicalnewstoday.com —

Morphosys ag (fse: mor; prime standard segment, tecdax) announced that it has enrolled the first patient in its phase 1b/2a clinical trial of its lead drug mor103. the company's lead development p

View full resource at medicalnewstoday.com

Tags: Arthritis, Rheumatoid Arthritis, Drug, Clinical Trial

  • Share

Most Recently Shared on January 19, 2010 at 4:27 pm By:

mnt_clinical MNT Clinical Trials

MorphoSys Enrolls First Patient In Phase 1b/2a Clinical Trial For MOR103 Program In Rheumatoid Arthritis http://mnt.to/3wvh

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Arthritis News MNT Arthritis News

Advertisement